HUNAN JIUDIAN PHARMACEUTICAL CO., LTD. |
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 36.81 CNY | +1.63% |
|
+2.00% | +10.77% |
Valuation
| Fiscal Period: December | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|
| Capitalization 1 | 6,289 | 8,247 | 8,333 | 11,469 | 12,705 | - | - |
| Enterprise Value (EV) 1 | 6,289 | 8,247 | 8,333 | 11,469 | 12,705 | 12,705 | 12,705 |
| P/E ratio | 78.8 x | 40.4 x | 29.6 x | 31.1 x | 25 x | 19.6 x | 14.2 x |
| Yield | - | 0.74% | 0.97% | 0.97% | 0.49% | 0.6% | - |
| Capitalization / Revenue | - | 5.07 x | 3.58 x | 4.26 x | 3.82 x | 3.12 x | 2.94 x |
| EV / Revenue | - | 5.07 x | 3.58 x | 4.26 x | 3.82 x | 3.12 x | 2.94 x |
| EV / EBITDA | - | 29.4 x | 23.7 x | 24.6 x | 17.9 x | 15.2 x | 11.3 x |
| EV / FCF | - | - | - | - | - | - | - |
| FCF Yield | - | - | - | - | - | - | - |
| Price to Book | - | 8.01 x | 5.37 x | 6.07 x | 5.48 x | 4.4 x | 3.51 x |
| Nbr of stocks (in thousands) | 328,552 | 328,552 | 342,936 | 345,145 | 345,148 | - | - |
| Reference price 2 | 19.14 | 25.10 | 24.30 | 33.23 | 36.81 | 36.81 | 36.81 |
| Announcement Date | 2/28/21 | 4/26/22 | 4/14/23 | 4/24/24 | - | - | - |
1CNY in Million2CNY
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: December | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|
| Net sales 1 | - | 1,628 | 2,326 | 2,693 | 3,323 | 4,073 | 4,315 |
| EBITDA 1 | - | 280.4 | 352 | 467 | 711.6 | 833.6 | 1,123 |
| EBIT 1 | - | 225.8 | 291.3 | 394.4 | 553.4 | 708.2 | 971.6 |
| Operating Margin | - | 13.87% | 12.52% | 14.65% | 16.65% | 17.39% | 22.51% |
| Earnings before Tax (EBT) 1 | - | 226.2 | 290.2 | 402.2 | 556 | 716.4 | 975.3 |
| Net income 1 | 80.28 | 204.2 | 269.7 | 368.3 | 509 | 647.2 | 893.7 |
| Net margin | - | 12.55% | 11.59% | 13.68% | 15.32% | 15.89% | 20.71% |
| EPS 2 | 0.2429 | 0.6214 | 0.8200 | 1.070 | 1.470 | 1.882 | 2.590 |
| Free Cash Flow | - | - | - | - | - | - | - |
| FCF margin | - | - | - | - | - | - | - |
| FCF Conversion (EBITDA) | - | - | - | - | - | - | - |
| FCF Conversion (Net income) | - | - | - | - | - | - | - |
| Dividend per Share 2 | - | 0.1864 | 0.2360 | 0.3210 | 0.1800 | 0.2200 | - |
| Announcement Date | 2/28/21 | 4/26/22 | 4/14/23 | 4/24/24 | - | - | - |
1CNY in Million2CNY
Estimates
Balance Sheet Analysis
| Fiscal Period: December | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|
| Net Debt | - | - | - | - | - | - | - |
| Net Cash position | - | - | - | - | - | - | - |
| Leverage (Debt/EBITDA) | - | - | - | - | - | - | - |
| Free Cash Flow | - | - | - | - | - | - | - |
| ROE (net income / shareholders' equity) | - | 20.9% | 18.6% | 21.2% | 21.6% | 22.4% | 24.4% |
| ROA (Net income/ Total Assets) | - | 14.2% | 13.3% | - | 16.7% | 17.1% | - |
| Assets 1 | - | 1,438 | 2,022 | - | 3,043 | 3,778 | - |
| Book Value Per Share 2 | - | 3.140 | 4.530 | 5.470 | 6.710 | 8.370 | 10.50 |
| Cash Flow per Share 2 | - | 0.5800 | 0.7800 | 1.250 | 1.680 | 1.740 | 2.920 |
| Capex 1 | - | 126 | 413 | 427 | 56 | 52.5 | - |
| Capex / Sales | - | 7.72% | 17.77% | 15.85% | 1.68% | 1.29% | - |
| Announcement Date | 2/28/21 | 4/26/22 | 4/14/23 | 4/24/24 | - | - | - |
1CNY in Million2CNY
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Year-on-year evolution of the Yield
Change in Enterprise Value/EBITDA
Trading Rating
Investor Rating
ESG Refinitiv
Sell
Buy
Mean consensus
BUY
Number of Analysts
5
Last Close Price
36.81
Average target price
-
EPS Revisions
Annual profits - Rate of surprise
| 1st Jan change | Capi. | |
|---|---|---|
| +10.77% | 1.75B | |
| +26.47% | 664B | |
| +26.74% | 567B | |
| -6.33% | 354B | |
| +19.35% | 330B | |
| +4.23% | 286B | |
| +13.43% | 234B | |
| +4.71% | 199B | |
| -9.53% | 196B | |
| -4.04% | 148B |
- Stock Market
- Equities
- 300705 Stock
- Financials Hunan Jiudian Pharmaceutical Co., Ltd.
